Protalix BioTherapeutics, Inc. Common Stock
PLXProtalix BioTherapeutics, Inc. is an Israeli biopharmaceutical company specializing in the development and commercialization of plant cell-based recombinant protein production technology. The company's technology platform aims to create cost-effective and scalable treatments for rare and ultra-rare orphan diseases. Protalix is known for its focus on enzyme replacement therapies and has developed products such as taliglucerase alfa for Gaucher disease.
Company News
The European Commission has approved a new every-4-weeks dosing regimen (2mg/kg) for Elfabrio® (pegunigalsidase alfa) in adults with Fabry disease who are stable on enzyme replacement therapy. This approval extends the infusion interval from every 2 weeks, reducing treatment burden for patients and healthcare systems. Protalix is entitled to a $...
The global Fabry disease treatment market is expected to grow from $2.76 billion in 2024 to $7.02 billion by 2034, at a CAGR of 9.8%. Key factors driving the market include FDA clearance of Fabry disease drugs and increased R&D investment.
Pluxee to acquire Cobee, an innovative Spanish digital player in Employee Benefits
Pluxee signe un accord pour l’acquisition de Cobee, un acteur digital espagnol innovant des avantages aux salariés
Pluxee firma un acuerdo para adquirir Cobee, empresa digital e innovadora de origen español especializada en beneficios para empleados
